Anti-cancer activity of plant-produced HPV16 E7 vaccine

TitleAnti-cancer activity of plant-produced HPV16 E7 vaccine
Publication TypeArticolo su Rivista peer-reviewed
Year of Publication2007
AuthorsMassa, Silvia, Franconi Rosella, Brandi R., Muller A., Mett V., Yusibov V., and Venuti A.
JournalVaccine
Volume25
Pagination3018-3021
ISSN0264410X
Keywords1, 3 beta glucanase, 4 beta glucanase, animal experiment, animal model, Animals, antineoplastic activity, article, Cancer Vaccines, Clostridium thermocellum, controlled study, cytotoxic T lymphocyte, Experimental, Female, glucan glucosidase, Human papillomavirus type 16, immunoglobulin G antibody, Inbred C57BL, Mice, mouse, Neoplasms, Nicotiana benthamiana, nonhuman, nucleotide sequence, Oncogene Proteins, Papillomaviridae, priority journal, protein E7, protein e7ggg, Recombinant Fusion Proteins, Tobacco, transient expression, Tumor, unclassified drug, Viral, Viral Vaccines, Wart virus vaccine
Abstract

The E7 oncoprotein from Human Papilloma Virus (HPV) is an attractive candidate for anti-cancer vaccine development. In this study, we engineered HPV16 E7 coding sequence (wild type or mutagenized sequence, E7GGG) as fusions to β-1,3-1,4-glucanase (LicKM) of Clostridium thermocellum and produced in Nicotiana benthamiana plants using a transient expression system. Target antigens were purified and evaluated in mice for their potential as prophylactic and therapeutic vaccine candidates. Both fusion proteins induced E7-specific IgG and cytotoxic T-cell responses and protected mice against challenge with E7-expressing tumor cells. Furthermore, when administered after challenge, these plant-produced antigens prevented tumor development. © 2007 Elsevier Ltd. All rights reserved.

Notes

cited By 60

URLhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-33947717551&doi=10.1016%2fj.vaccine.2007.01.018&partnerID=40&md5=62c73b11b14e709ba0fc51d727bec716
DOI10.1016/j.vaccine.2007.01.018